We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Endpoint Analysis in Eosinophilic Esophagitis Trials Gets FDA Overhaul
Endpoint Analysis in Eosinophilic Esophagitis Trials Gets FDA Overhaul
Sponsors of clinical trials for drugs or biologics to treat eosinophilic esophagitis, a chronic disease in which white blood cells inflame the esophagus, should note a change to how the FDA recommends they analyze the data.